Trial Profile

An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; LBL-024 (Primary)
Indications Neuroendocrine carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors Nanjing Leads Biolabs

31 May 2025 Results presented in the Leads Biolabs Media Release.
31 May 2025 According to a Leads Biolabs media release, results from this trial were presented at the ASCO 2025.
14 Nov 2024 Protocol amendment with addition on additional cohort and addition of Atezolizumab in combination therapy. Patients no. increased to 178.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com